Literature DB >> 2548552

Effects of ACE inhibition with cilazapril on splanchnic and systemic haemodynamics in man.

S Gasic1, G Heinz, C Kleinbloesem, A Korn.   

Abstract

1. There is recent experimental evidence that the renin-angiotensin-system may play an essential role in producing splanchnic vasoconstriction. However, controversy exists as to the influence of ACE inhibition on splanchnic haemodynamics in man. We therefore investigated whether cilazapril, a structurally new and long-acting ACE inhibitor, interacts with angiotensin I-dependent changes in splanchnic haemodynamics in man, using an experimental model. 2. The effects of cilazapril on angiotensin I-induced splanchnic and systemic haemodynamics were studied in seven normotensive men using the hepatic venous catheter technique (indocyanine-green dye), right-heart catheterisation (thermodilution method), intra-arterial blood pressure monitoring and systolic time-intervals. Dose-responses to angiotensin I were determined under control conditions and 60 min after ACE inhibition with 5 mg oral cilazapril. Angiotensin I was infused intravenously at constant rates in an increasing dose-sequence until systolic blood pressure was greater than 30 mm Hg. 3. ACE inhibition with cilazapril did not change basal splanchnic or systemic haemodynamics to any relevant extent. The angiotensin I dependent increase in systemic and pulmonary resistance and pulmonary capillary wedge pressure was attenuated by cilazapril, as indicated by the shift of the dose-response curves to the right. In the splanchnic vascular bed angiotensin I dose-dependently increased splanchnic vascular resistance and also wedge hepatic venous pressure and decreased splanchnic blood flow. These angiotensin I induced haemodynamic changes were clearly suppressed by cilazapril. The angiotensin I dose needed to produce a 30% increase in splanchnic vascular resistance, given as mean and s.e. mean, was 1.7 +/- 0.3 micrograms min-1 during control-trials vs 7.3 +/- 1.3 micrograms min-1 after ACE inhibition with cilazapril (P less than 0.001). 4. We conclude that, in man, the influence of cilazapril on acute angiotensin I-mediated haemodynamic responses is present in the splanchnic vascular bed, and that the overall effects of cilazapril are consistent with both arterial and venous effects of the ACE inhibitor. Cilazapril effectively counteracts angiotensin I-induced splanchnic vasoconstriction.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2548552      PMCID: PMC1379752          DOI: 10.1111/j.1365-2125.1989.tb03486.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  28 in total

1.  Angiotensin II, aldosterone and arginine vasopressin in plasma in congestive heart failure.

Authors:  E B Pedersen; H Danielsen; T Jensen; M Madsen; S S Sørensen; O O Thomsen
Journal:  Eur J Clin Invest       Date:  1986-02       Impact factor: 4.686

2.  Protection of the small intestine from nonocclusive mesenteric ischemic injury due to cardiogenic shock.

Authors:  R W Bailey; G B Bulkley; S R Hamilton; J B Morris; U H Haglund
Journal:  Am J Surg       Date:  1987-01       Impact factor: 2.565

3.  Intestinal vasoconstriction after hemorrhage: roles of vasopressin and angiotensin.

Authors:  J R McNeill; R D Stark; C V Greenway
Journal:  Am J Physiol       Date:  1970-11

4.  Assessment of Peripheral adrenergic activity and its interactions with drugs in man.

Authors:  K Ghose
Journal:  Eur J Clin Pharmacol       Date:  1980-04       Impact factor: 2.953

5.  Acute and long-term response to an oral converting-enzyme inhibitor, captopril, in congestive heart failure.

Authors:  T B Levine; J A Franciosa; J N Cohn
Journal:  Circulation       Date:  1980-07       Impact factor: 29.690

6.  Effects of ACE-inhibition on regional circulation in congestive heart failure.

Authors:  K Swedberg
Journal:  Acta Med Scand Suppl       Date:  1986

7.  Insulin production rate following glucose ingestion estimated by splanchnic C-peptide output in normal man.

Authors:  W Waldhäusl; P Bratusch-Marrain; S Gasic; A Korn; P Nowotny
Journal:  Diabetologia       Date:  1979-10       Impact factor: 10.122

8.  Biological properties of the angiotensin-converting enzyme inhibitor cilazapril.

Authors:  I L Natoff; J S Nixon; R J Francis; L R Klevans; M Brewster; J Budd; A T Patel; J Wenger; E Worth
Journal:  J Cardiovasc Pharmacol       Date:  1985 May-Jun       Impact factor: 3.105

9.  Effect of pentobarbital anesthesia and surgery on the control of arterial pressure and mesenteric resistance in cats: role of vasopressin and angiotensin.

Authors:  J R McNeill; C C Pang
Journal:  Can J Physiol Pharmacol       Date:  1982-03       Impact factor: 2.273

10.  The effects of indecainide, a new antidysrhythmic drug, on nodal tissues in the isolated rabbit heart.

Authors:  P D Dennis; E M Vaughan Williams
Journal:  J Cardiovasc Pharmacol       Date:  1986 Jan-Feb       Impact factor: 3.105

View more
  1 in total

Review 1.  Understanding gastrointestinal perfusion in critical care: so near, and yet so far.

Authors:  G Ackland; M P Grocott; M G Mythen
Journal:  Crit Care       Date:  2000-09-01       Impact factor: 9.097

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.